Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 8/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 7/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.47 |
| ▸ | MIF | P14174 | 3/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | BACH1 | O14867 | 1/20 | 0.46 |
| ▸ | MAFK | O60675 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL362346 | 0.79 | KEAP1 (0.50) | TRPA1KEAP1NFE2L2MIFNAAA | |
| SCHEMBL3109402 | 0.77 | MIF (0.52) | TRPA1KEAP1NFE2L2MIFNAAA | |
| SCHEMBL3120743 | 0.76 | NAAA (0.52) | TRPA1KEAP1NFE2L2MIFNAAA | |
| SCHEMBL3117317 | 0.75 | MIF (0.56) | TRPA1KEAP1NFE2L2MIFNAAA | |
| SCHEMBL1805417 | 0.75 | MIF (0.56) | TRPA1KEAP1NFE2L2MIFNAAA | |
| SCHEMBL3128515 | 0.74 | NAAA (0.55) | TRPA1KEAP1NFE2L2MIFNAAA | |
| SCHEMBL3119816 | 0.74 | NAAA (0.61) | TRPA1KEAP1NFE2L2MIFNAAA | |
| SCHEMBL17519951 | 0.74 | TSHR (0.52) | TRPA1KEAP1NFE2L2MIFNAAA | |
| Hydrochloric Acid SCHEMBL9698829 | 0.73 | MIF (0.54) | TRPA1KEAP1NFE2L2MIFNAAA | |
| SCHEMBL9698334 | 0.73 | MIF (0.54) | TRPA1KEAP1NFE2L2MIFNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046530-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | KONSTANTOPOULOS KONSTANTINOS (US) | 2019-02-14 | — | — | US | disclosed |
| US-20160038485-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | TALALAY, PAUL | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190046530-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | PTGS2, PTGES2, CCAR2 | TRPA1 388/4885KEAP1 393/4885NFE2L2 9/4885 |
| US-20160038485-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | PTGS2, PTGES2, CCAR2 | TRPA1 388/4885KEAP1 393/4885NFE2L2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.